Table 1.
Pretreatment and post-treatment patient characteristics.
| Pretreatment patient characteristics |
Post-treatment patient characteristics |
|||||
|---|---|---|---|---|---|---|
| PD (n = 45, 3.8%) |
non-PD (n = 1142, 96.2%) |
PD (n = 45, 3.8%) |
non-PD (n = 1142, 96.2%) |
|||
| Characteristic | No. of Patients (%) | No. of Patients (%) | P | No. of Patients (%) | No. of Patients (%) | P |
| Age, years | .325 | |||||
| Median | 48 (-) | 49 (-) | - | - | ||
| Range | 21–65 | 23–76 | - | - | ||
| Menopausal status | .180 | |||||
| Premenopausal | 30 (66.7) | 646 (56.6) | - | - | ||
| Postmenopausal | 15 (33.3) | 496 (43.4) | - | - | ||
| Family history of cancer | .497 | |||||
| Breast cancer | 2 (4.4) | 37 (3.2) | - | - | ||
| Other cancers | 6 (13.3) | 226 (19.8) | - | - | ||
| No | 37 (82.2) | 872 (76.4) | - | - | ||
| Unknown | 0 (0.0) | 7 (0.6) | - | - | ||
| BMI a | .411 | |||||
| Median | 23.2 (-) | 23.5 (-) | - | - | ||
| Range | 14.9–30.8 | 15.6–34.9 | - | - | ||
| Ki-67 score b | .001 | |||||
| Median | 50.00 (-) | 30.00 (-) | - | - | ||
| Range | 5–90 | 0-95 | - | - | ||
| ER status | .001 | |||||
| Negative | 31 (68.9) | 465 (41.5) | - | - | ||
| Positive | 14 (31.1) | 656 (58.5) | - | - | ||
| Unknown | 0 (0) | 21 (1.8) | - | - | ||
| PR status | .016 | |||||
| Negative | 32 (71.1) | 568 (49.7) | - | - | ||
| Positive | 13 (28.9) | 550 (48.2) | - | - | ||
| Unknown | 0 (0.0) | 24 (2.1) | - | - | ||
| Her-2 status | .884 | |||||
| Negative | 21 (46.7) | 563 (49.3) | - | - | ||
| Positive | 16 (35.6) | 416 (36.4) | - | - | ||
| Uncertain | 6 (13.3) | 132 (11.6) | - | - | ||
| Unknown | 2 (4.4) | 31 (2.7) | - | - | ||
| Histology | .000 | |||||
| Ductal | 34 (75.6) | 1074 (94.0) | - | - | ||
| Lobular | 2 (4.4) | 14 (1.2) | - | - | ||
| Mixed | 5 (11.1) | 21 (1.8) | - | - | ||
| Other | 4 (8.9) | 23 (2.0) | - | - | ||
| Unknown | 0 (0.0) | 10 (0.9) | - | - | ||
| Nuclear grade | .000 | |||||
| I | 0 (0.0) | 21 (1.8) | - | - | ||
| II | 4 (8.9) | 217 (19.0) | - | - | ||
| III | 14 (31.1) | 117 (10.2) | - | - | ||
| Unknown | 27 (60.0) | 787 (68.9) | - | - | ||
| Tumor size, mm | .133 | <.001 | ||||
| Median | 38.0 (-) | 34.5 (-) | 55.0 | 20.0 | ||
| Range | 13.0–130.0 | 5.0–160.0 | 0–230 | 0–120 | ||
| T stage | .006 | <.001 | ||||
| T0 | - | - | 1 (2.2) | 176 (15.4) | ||
| Tis | - | - | 0 (0.0) | 19 (1.7) | ||
| T1 | 4 (8.9) | 77 (6.7) | 5 (11.1) | 490 (42.9) | ||
| T2 | 19 (42.2) | 760 (66.5) | 13 (28.9) | 356 (31.2) | ||
| T3 | 13 (28.9) | 159 (13.9) | 13 (28.9) | 55 (4.8) | ||
| T4 | 9 (20.0) | 146 (12.8) | 13 (28.9) | 46 (4.0) | ||
| N stage | .622 | .003 | ||||
| N0 | 7 (15.6) | 136 (11.9) | 9 (20.0) | 366 (32.0) | ||
| N1 | 28 (62.2) | 657 (57.5) | 13 (28.9) | 325 (28.5) | ||
| N2 | 7 (15.6) | 222 (19.4) | 6 (13.3) | 254 (22.2) | ||
| N3 | 3 (6.7) | 127 (11.1) | 17 (37.8) | 197 (17.3) | ||
| AJCC stage | .237 | <.001 | ||||
| 0 | - | - | 1 (2.2) | 132 (11.6) | ||
| IA | 0 (0.0) | 1 (0.1) | 1 (2.2) | 153 (13.4) | ||
| IIA | 8 (17.8) | 140 (12.3) | 6 (13.3) | 269 (23.6) | ||
| IIB | 12 (26.7) | 476 (41.7) | 8 (17.8) | 117 (10.2) | ||
| IIIA | 14 (31.1) | 272 (23.8) | 6 (13.3) | 245 (21.5) | ||
| IIIB | 8 (17.8) | 128 (11.2) | 6 (13.3) | 30 (2.6) | ||
| IIIC | 3 (6.7) | 125 (10.9) | 14 (31.1) | 196 (17.2) | ||
| IV | - | - | 3 (6.7) | 0 (0.0) | ||
| Lymphovascular invasion | .178 | |||||
| Positive | - | - | 20 (44.4) | 396 (34.7) | ||
| Negative | - | - | 25 (55.6) | 746 (65.3) | ||
| Chemotherapy regimen | ||||||
| Anthracycline-based | - | - | 37 (82.2) | 1016 (89.0) | .161 | |
| Taxane-based | - | - | 31 (68.9) | 1040 (91.1) | .000 | |
| Trastuzumab | - | - | 2 (4.4) | 117 (10.2) | .309 | |
| Surgery | .792 | |||||
| BCT | - | - | 1 (2.2) | 33 (2.9) | ||
| Mastectomy | - | - | 44 (97.8) | 1109 (97.1) | ||
Abbreviations: PD, progressive disease; BMI, body mass index; AJCC, American Joint Committee on Cancer; ER, estrogen receptor; PR, progesterone receptor; HER-2, human epidermal growth factor receptor 2; BCT, breast-conserving therapy.
aBMI was available in 45 patients in the PD group and 1136 patients in the non-PD group.
bKi-67 scores were available in 27 patients in the PD group and 712 patients in the non-PD group.